타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Lucentis (ranibizumab) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | VEGF-A |
Overview Indication | Wet AMD, DME, RVO, myopic CNV |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1 |
Positioning Known limitation | Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents. |
MoA Mechanism | Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema. |
MoA Biomarker | biomarker of treatment response, supporting further validation in larger independent cohorts |
Toxicology Major finding | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). |
Toxicology CRS | N/A |
Clinical Safety signal | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Lucentis (ranibizumab) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | VEGF-A |
Overview Indication | Wet AMD, DME, RVO, myopic CNV |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1 |
Positioning Known limitation | Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents. |
MoA Mechanism | Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema. |
MoA Biomarker | biomarker of treatment response, supporting further validation in larger independent cohorts |
Toxicology Major finding | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). |
Toxicology CRS | N/A |
Clinical Safety signal | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교